Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
COGT Cogent Biosciences	$12.37 -0.6%	$7.67	$3.72 ▼ $12.97	$1.42B	1.88	1.65 million shs	2.95 million shs
CRSP CRISPR Therapeutics	$68.14 +3.4%	$46.45	$30.04 ▼ $71.13	$5.69B	1.82	2.03 million shs	3.78 million shs
CYTK Cytokinetics	$37.93 +0.6%	$33.43	$29.31 ▼ $61.38	$4.50B	0.59	1.53 million shs	934,214 shs
PCVX Vaxcyte	$36.46 +2.1%	$34.18	$27.66 ▼ $121.06	$4.61B	1.19	1.50 million shs	728,815 shs

Ten Starter Stocks For Beginners to Buy Now

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
COGT Cogent Biosciences	-0.64%	+4.30%	+70.39%	+174.28%	+35.78%
CRSP CRISPR Therapeutics	+3.35%	+23.58%	+49.59%	+74.23%	+19.15%
CYTK Cytokinetics	+0.61%	-1.94%	+16.21%	-5.95%	-33.90%
PCVX Vaxcyte	+2.07%	-0.30%	+9.65%	+5.65%	-56.57%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
COGT Cogent Biosciences	3.4131 of 5 stars	4.4	3.0	0.0	2.1	1.7	0.6
CRSP CRISPR Therapeutics	1.7646 of 5 stars	2.3	1.0	0.0	3.1	3.3	0.6
CYTK Cytokinetics	4.2625 of 5 stars	4.5	1.0	4.6	3.2	0.8	0.0
PCVX Vaxcyte	1.8979 of 5 stars	3.6	1.0	0.0	2.6	1.7	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
COGT Cogent Biosciences	2.82	Moderate Buy	$18.70	51.17% Upside
CRSP CRISPR Therapeutics	2.53	Moderate Buy	$71.31	4.66% Upside
CYTK Cytokinetics	2.93	Moderate Buy	$70.92	86.98% Upside
PCVX Vaxcyte	3.10	Buy	$136.50	274.38% Upside

Current Analyst Ratings Breakdown

Latest COGT, CRSP, PCVX, and CYTK Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/22/2025	CRSP CRISPR Therapeutics	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$79.00 ➝ $78.00
7/18/2025	COGT Cogent Biosciences	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$15.00 ➝ $22.00
7/10/2025	COGT Cogent Biosciences	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$25.00 ➝ $29.00
7/8/2025	COGT Cogent Biosciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$12.00 ➝ $22.00
7/8/2025	COGT Cogent Biosciences	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$17.00
7/8/2025	COGT Cogent Biosciences	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$7.00 ➝ $9.00
7/8/2025	CRSP CRISPR Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$81.00
7/7/2025	COGT Cogent Biosciences	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$23.00 ➝ $28.00
7/7/2025	COGT Cogent Biosciences	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$16.00 ➝ $18.00
6/30/2025	COGT Cogent Biosciences	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral	$10.00
6/27/2025	CRSP CRISPR Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$105.00

(Data available from 7/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
COGT Cogent Biosciences	N/A	N/A	N/A	N/A	$1.32 per share	N/A
CRSP CRISPR Therapeutics	$37.31M	157.72	N/A	N/A	$22.64 per share	3.01
CYTK Cytokinetics	$18.47M	245.26	N/A	N/A	($1.15) per share	-32.98
PCVX Vaxcyte	N/A	N/A	N/A	N/A	$26.52 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
COGT Cogent Biosciences	-$255.86M	-$1.84	N/A	N/A	N/A	N/A	-149.79%	-75.61%	8/5/2025 (Estimated)
CRSP CRISPR Therapeutics	-$366.25M	-$4.52	N/A	N/A	N/A	-1,023.64%	-20.08%	-17.13%	8/4/2025 (Estimated)
CYTK Cytokinetics	-$589.53M	-$5.29	N/A	N/A	N/A	-3,201.47%	N/A	-43.75%	8/6/2025 (Estimated)
PCVX Vaxcyte	-$463.93M	-$3.99	N/A	N/A	N/A	N/A	-17.12%	-16.26%	8/5/2025 (Estimated)

Latest COGT, CRSP, PCVX, and CYTK Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	CYTK Cytokinetics	-$1.32	N/A	N/A	N/A	N/A	N/A
8/5/2025	Q2 2025	COGT Cogent Biosciences	-$0.54	N/A	N/A	N/A	N/A	N/A
8/5/2025	Q2 2025	PCVX Vaxcyte	-$1.12	N/A	N/A	N/A	N/A	N/A
8/4/2025	Q2 2025	CRSP CRISPR Therapeutics	-$1.54	N/A	N/A	N/A	$6.44 million	N/A
5/14/2025	Q1 2025	PCVX Vaxcyte	-$1.02	-$1.04	-$0.02	-$1.04	N/A	N/A
5/6/2025	Q1 2025	COGT Cogent Biosciences	-$0.56	-$0.52	+$0.04	-$0.52	N/A	N/A
5/6/2025	Q1 2025	CRSP CRISPR Therapeutics	-$1.27	-$1.58	-$0.31	-$1.58	N/A	N/A
5/6/2025	Q1 2025	CYTK Cytokinetics	-$1.41	-$1.36	+$0.05	-$1.36	$2.77 million	$1.60 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
COGT Cogent Biosciences	N/A	N/A	N/A	N/A	N/A
CRSP CRISPR Therapeutics	N/A	N/A	N/A	N/A	N/A
CYTK Cytokinetics	N/A	N/A	N/A	N/A	N/A
PCVX Vaxcyte	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
COGT Cogent Biosciences	N/A	5.13	5.13
CRSP CRISPR Therapeutics	N/A	15.64	15.64
CYTK Cytokinetics	N/A	5.99	5.99
PCVX Vaxcyte	N/A	17.70	17.70

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
COGT Cogent Biosciences	N/A
CRSP CRISPR Therapeutics	69.20%
CYTK Cytokinetics	N/A
PCVX Vaxcyte	96.78%

Insider Ownership

Company	Insider Ownership
COGT Cogent Biosciences	7.29%
CRSP CRISPR Therapeutics	4.30%
CYTK Cytokinetics	2.70%
PCVX Vaxcyte	3.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
COGT Cogent Biosciences	80	113.86 million	105.56 million	Optionable
CRSP CRISPR Therapeutics	460	86.36 million	82.65 million	Optionable
CYTK Cytokinetics	250	119.43 million	116.20 million	Optionable
PCVX Vaxcyte	160	129.00 million	125.01 million	Optionable

COGT, CRSP, PCVX, and CYTK Headlines

Recent News About These Companies

New York State Common Retirement Fund Increases Holdings in Vaxcyte, Inc. (NASDAQ:PCVX)

July 22 at 5:58 AM | marketbeat.com

Jennison Associates LLC Has $42.51 Million Stock Holdings in Vaxcyte, Inc. (NASDAQ:PCVX)

July 20, 2025 | marketbeat.com

C WorldWide Group Holding A S Makes New $3.59 Million Investment in Vaxcyte, Inc. (NASDAQ:PCVX)

July 18, 2025 | marketbeat.com

Mizuho Maintains an Overweight Rating on Vaxcyte (PCVX)

July 16, 2025 | insidermonkey.com

Vaxcyte, Inc. (NASDAQ:PCVX) Shares Sold by TimesSquare Capital Management LLC

July 15, 2025 | marketbeat.com

Principal Financial Group Inc. Has $17.73 Million Holdings in Vaxcyte, Inc. (NASDAQ:PCVX)

July 11, 2025 | marketbeat.com

Brown Advisory Inc. Acquires 14,049 Shares of Vaxcyte, Inc. (NASDAQ:PCVX)

July 10, 2025 | marketbeat.com

Allspring Global Investments Holdings LLC Lowers Holdings in Vaxcyte, Inc. (NASDAQ:PCVX)

July 4, 2025 | marketbeat.com

Cantor Fitzgerald Maintains Overweight on Vaxcyte Amid Vaccine Development and ACIP Meeting

July 2, 2025 | msn.com

86,244 Shares in Vaxcyte, Inc. (NASDAQ:PCVX) Acquired by Peregrine Capital Management LLC

July 2, 2025 | marketbeat.com

Vaxcyte, Inc. (NASDAQ:PCVX) Given Average Recommendation of "Buy" by Brokerages

June 30, 2025 | marketbeat.com

Vaxcyte: Sentiment Is Pushing The Shares Down

June 10, 2025 | seekingalpha.com

Here’s Why Vaxcyte (PCVX) Sold Off in Q1

May 27, 2025 | msn.com

Is Vaxcyte, Inc. (PCVX) The Best Stock That Will Bounce Back?

May 9, 2025 | insidermonkey.com

Vaxcyte Reports First Quarter 2025 Financial Results and Provides Business Update

May 7, 2025 | globenewswire.com

Vaxcyte appoints new independent director

May 3, 2025 | uk.investing.com

Vaxcyte Appoints Dr. Olivier Brandicourt to Board

May 1, 2025 | tipranks.com

Vaxcyte, Inc. Appoints Dr. Olivier Brandicourt to Board of Directors to Advance Vaccine Development

May 1, 2025 | quiverquant.comQ

Vaxcyte Appoints Dr. Olivier Brandicourt to Board of Directors

May 1, 2025 | globenewswire.com

Is Vaxcyte, Inc. (PCVX) the Best Oversold NASDAQ Stock to Buy Right Now?

April 29, 2025 | insidermonkey.com

Commit To Buy Vaxcyte At $20, Earn 14.7% Annualized Using Options

April 23, 2025 | nasdaq.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

COGT, CRSP, PCVX, and CYTK Company Descriptions

Cogent Biosciences NASDAQ:COGT

$12.37 -0.08 (-0.64%)

Closing price 07/23/2025 04:00 PM Eastern

Extended Trading

$12.00 -0.37 (-2.99%)

As of 05:30 AM Eastern

Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.

CRISPR Therapeutics NASDAQ:CRSP

$68.14 +2.21 (+3.35%)

Closing price 07/23/2025 04:00 PM Eastern

Extended Trading

$69.76 +1.62 (+2.38%)

As of 05:39 AM Eastern

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.

Cytokinetics NASDAQ:CYTK

$37.93 +0.23 (+0.61%)

Closing price 07/23/2025 04:00 PM Eastern

Extended Trading

$37.72 -0.21 (-0.55%)

As of 07/23/2025 07:20 PM Eastern

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated has a strategic alliance with Ji Xing Pharmaceuticals Limited. The company was incorporated in 1997 and is headquartered in South San Francisco, California.

Vaxcyte NASDAQ:PCVX

$36.46 +0.74 (+2.07%)

Closing price 07/23/2025 04:00 PM Eastern

Extended Trading

$36.00 -0.46 (-1.26%)

As of 07/23/2025 04:20 PM Eastern

Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time